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Abstract Pompe disease, especially in its infantile form, is
a fatal disease. Most of the patients with this disease
synthesize a nonfunctional form of the enzyme alpha
glucosidase (GAA), the deficient enzyme in this disease.
Patients producing some amount of this protein are labeled
as cross-reactive immunologic material (CRIM)-positive.
Few of them are unable to synthesize it and are labeled
CRIM-negative. The clinical course of the disease has
changed with the advent of enzyme replacement therapy
(ERT) with recombinant alpha glucosidase enzyme
(rhGAA). However, CRIM-negative patients have always
been known to have poor outcome on ERT due to the
development of anti-rhGAA antibodies in their bodies that
neutralizes ERT efficacy. Here, we describe two CRIM-
negative siblings on rhGAA ERT with unusually low anti-
rhGAA antibody titer and good clinical outcome. Up to our
current knowledge, this is the first report that describes such
a good response to ERT in CRIM-negative patients.
Abbreviations
CRIM Cross reactive immunologic material
ERT Enzyme replacement therapy
GAA Acid alpha glucosidase
rhGAA Recombinant human acid alpha glucosidase
Introduction
Pompe disease (glycogen storage disease type II) is an
autosomal recessive lysosomal storage disease caused by
deficiency of acid a-glucosidase (GAA). As a consequence,
its substrate glycogen accumulates in cardiac, skeletal, and
smooth muscle tissues. The infantile form, which is the
most severe phenotype, presents clinically with cardiomy-
opathy, hypotonia, generalized muscle weakness, feeding
difficulties, failure to thrive, and respiratory insufficiency.
GAA protein is called cross-reactive immunologic
material (CRIM) because anti-GAA antibodies recognize
it on Western blot analysis. Most Pompe patients still have
some residual GAA protein production and are labeled as
CRIM positive while those with total absence of that
protein are labeled CRIM negative (Amalfitano et al. 2001).
Without treatment, death typically occurs with the first 1 to
2 years secondary to cardiorespiratory failure (Van den
Hout et al. 2003). Enzyme replacement therapy (ERT) with
recombinant acid a-glucosidase (rhGAA) has been shown
to prolong these patients’ lives (Kishnani et al. 2007, 2009;
Nicolino et al. 2009). However, the response of these
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patients to rhGAA treatment depends on their CRIM status.
CRIM-negative infants generally have a poor prognosis,
where they have been found to have an initial improvement
followed by a clinical deterioration. Their deterioration has
been attributed to the high levels of anti-rhGAA IgG
antibodies their bodies develop against the recombinant
enzyme. Conversely, CRIM-positive infants have a more
favorable prognosis and their anti-rhGAA antibodies are
not as significantly elevated as CRIM-negative ones
(Kishnani et al. 2010; Banugaria et al. 2011).
In this case report, we describe two siblings, brother and
sister, who are CRIM negative on a relatively long GAA
ERT with good outcome.
Patients and Methods
The patients are two African American CRIM-negative
siblings. The first is a 4.5-year-old boy while the second is
2-year-old girl.
CRIM status was determined as described previously
(Kishnani et al. 2006). Anti-rhGAA IgG antibody titer
measurements and CRIM status were performed at Gen-
zyme Corporation (Cambridge, MA). Leukocyte GAA
activity assays were performed at Emory University
Biochemical Genetics Laboratory. GAA mutation analysis
was performed at Emory University Molecular Genetics
Laboratory.
Results
The boy was a product of full-term pregnancy delivered via
cesarean section secondary to abnormal heart rate decelera-
tion. Soon after delivery, he was noted to be mildly
cyanotic and was given a diagnosis of transient tachypnea
of the newborn (TTN). A chest x-ray showed left ventricu-
lar enlargement. A follow-up echocardiogram showed
hypertrophic obstructive cardiomyopathy with mild left
ventricular outflow tract obstruction and mild mitral
regurgitation. He was started on propranolol, which lead
to improvement in the mitral regurgitation and left
ventricular outflow tract gradient. He was discharge on
propranolol 2 mg every 6 h to be followed bimonthly by
the cardiologist. Because of the progressive worsening of
his cardiomyopathy, his cardiologist referred him to our
genetics department to investigate for a possible genetic
cause of his condition, specifically to rule out Pompe
disease. When he was first seen in our genetics clinic, he
was 6 months old and his investigations showed total
creatine kinase (CPK) level of 2902 IU/L (normal: 60–305
IU/L) and CK MB fraction of 19.9 ng/mL (normal range:
0.0–3.3 ng/mL). Pompe disease was suspected and diag-
nosed on the basis of decreased leukocyte GAA activity
(0.3 nmoles/mg protein/h; normal: 6.01–37 nmoles/mg
protein/h) and confirmed by mutation analysis that showed
a deletion mutation in one allele (IVS2 +2_ +5 delTGGG
deletion in intron 2) and an insertion mutation
(c.1650_1651 dupG in exon 12) in the second. Western
blot testing on a skin fibroblast sample showed him to be
CRIM-negative.
Since his diagnosis was confirmed, he has been receiving
20 mg/kg rhGAA every 2 weeks, now for a total of 4 years on
treatment. His clinical course was complicated by one
hospital admission at the age of 1.5 years for pneumonia for
which he was intubated, but is now completely recovered.
Since that hospitalization, he has been followed annually
with a pulmonologist who prescribed him Levalbuterol and
Albuterol nebulizers. He has regular follow up with his
cardiologist. He still has mild intraventricular conductive
delay and mild hypertrophy. His echocardiogram showed
significant improvement since he was started on rhGAA
ERT; he currently has a ventricular septum of 7 mm, which
has been stable for the last 12 months, and is significantly
decreased compared to his highest measurement of 18 mm
just before the start of his ERT (Fig. 1a and b). His anti-
rhGAA antibody titers over the course of his ERT are
summarized in Fig. 2. During the course of his treatment,
he never had any infusion-related events even at the time of
his highest anti-rhGAA antibody titer.
He has mild developmental delay. He walked at the age
of 17 months. He receives physiotherapy and can run and
walk up and down stairs. He wears ankle-foot orthotic
braces now on a daily basis due to a development of foot
drop in the last year. He has been found to have low
vitamin D level, low borderline calcium, and elevated
parathyroid hormone. He is now on supplemental vitamin
D and calcium. His receptive language is normal but
expressive skills are delayed for which he is receiving
speech therapy. He has passed all his hearing tests so far.
Based on the positive family history, his sister’s
diagnosis was reached prenatally via mutational analysis
on amniocyte-isolated DNA where she was found to have
the same mutations as her brother. Her leukocyte GAA
activity was 1.02 nmoles/mg protein/h (normal: 6.01–37
nmoles/mg protein/h). At the age of 2 days, her CPK level
was found to be 1350 IU/L. Her echocardiogram was
consistent with severe obstructive cardiomyopathy for
which she was transferred to pediatric intensive care unit.
She has been receiving 20 mg/kg rhGAA every 2 weeks
since the age of 6 days, now on ERT for over 2 years. She
still has mild intraventricular conductive delay and T-wave
inversion in the anterolateral leads with features of
ventricular strain. Her last echocardiogram showed a
ventricular septum thickness of 5 mm, which has been
persistently decreasing from her highest, i.e., 11 mm at
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birth (Fig. 3a and b). She passed all her hearing tests so far
and has been developing normally with no hospitalization
or decompensation. Her anti-rhGAA antibody titers over
the course of her ERT are summarized in Fig. 2. Unlike her
brother, she had multiple infusion-related reactions in the
forms of hives that respond very well to 11 mg oral dose of
diphenhydramine hydrochloride and infusion time exten-
sion. None of these reactions were life threatening or severe
enough to stop the infusion or decrease its frequency.
Discussion
Since its approval for commercial use in 2006, ERT with
rhGAA has yielded significant change in the course of
infantile Pompe disease. It has been found, particularly in
CRIM-positive patients, to reverse cardiomyopathy, delay
or stabilize motor disease progression characterizing this
disease, and prolong ventilator-free survival (Banugaria
et al. 2011). Because of the high and sustained titers of
neutralizing anti rhGAA antibodies produced in their
bodies, CRIM-negative patients are known to benefit the
least from such therapy and they are either ventilator
dependent or deceased by age 27.1 months (Abbott et al.
2011). The longest CRIM-negative ventilator-free survival
was described in a single case report (Rohrbach et al. 2010)
in which the patient was treated with omalizumab (anti-IgE
mAb) for IgE-mediated anaphylactic episode related to
ERT. The elder CRIM-negative patient in our case report
has so far reached the age of 54 months, which is
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Fig. 2 Patients’ anti-rhGAA antibody titers over their corresponding duration of treatment
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the longest ever ventilator-free survival reported for a
CRIM-negative patient. In addition, he completed this
ventilator-free period of time without having any immuno-
modulatory intervention.
The nature of the mutation in these two siblings is a
candidate reason behind their favorable outcome to
enzyme treatment compared to other CRIM-negative
patients. Both mutations have recently been reported and
associated with CRIM-negative status (Bali et al. 2012).
To our knowledge, no study to correlate the type of
mutation in CRIM-negative patients with their response to
rhGAA ERT was published. In these two siblings, it is
possible that the product of the first mutation, a splice
mutation, might produce a quantity of the enzyme that is
too small to be detected by western blot and yet enough to
desensitize the patient’s immune system so that it would not
produce high titer of anti-rhGAA antibodies. Since the
second mutation is a frame shift mutation with nonesense
mutation 85 base pairs downstream, we do not expect a
protein to be produced by this mutation especially when we
take into consideration the nonesense-mediated messenger
RNA decay that occurs with such mutations.
The fact that the second sibling started her enzyme
therapy earlier than the first one, explains her lower anti-
rhGAA antibody titers compared to her brother who carries
the same mutations and points toward the importance of
early enzyme treatment.
This case report does not only describe a new pattern of
immunological response to rhGAA ERT but emphasizes the
fact that our understanding of that immunological process is
limited. It also proves that CRIM status is not the sole
immunological determinant of Pompe patients’ prognosis
on such treatment and reinforces the need to study the
genotype-phenotype correlation between CRIM-negative
mutations and the response to enzyme treatment.
With the availability of immunomodulatory regimens
(Joseph et al. 2008; Mendelsohn et al. 2009; Rohrbach et al.
2010; Messinger et al. 2012) to combat immunological
reaction against rhGAA that CRIM-negative patients
usually develop, it is clear from these two cases that not
all CRIM-negative patients need them; relying solely on
CRIM status to decide who should receive such immuno-
modulatory treatment might subject some CRIM-negative
patients to unnecessary immunosuppression. This issue
holds further importance as Pompe disease is being
proposed to be included on the newborn screening panel.
If added, consensus guidelines will be needed to address
timing of ERT initiation in CRIM-negative patients and if
immunomodulatory regimen should be used.
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